Abstract We performed a detailed morphologic, immunophenotypic, and endocrine characterization of neoplastic and non-neoplastic lesions of androgen-producing cells known to harbor or lack Reinke crystals (RCs) with an aim to provide further insight into the nature of these cells and crystals. Study cases were selected from the files of participating hospitals and subclassified according to current classifications: 20 with Leydig cell tumors (LCTs), 2 with testicular adrenal rest tumors (TARTs), 2 with testicular tumors of adrenogenital syndrome (TTAGS), and 2 with androgen insensitivity syndrome (AIS). An extensive immunophenotypic panel including markers used in sex cord-stromal cell tumors, androgen hormones, enzymes, and receptors was applied to the cases and 10 non-tumoral adrenal glands. Non-tumoral tissues were scored separately. RCs were present in 90 % of LCT cases and all cases with normal Leydig cells; RCs stained specifically with calretinin and 3β-hydroxysteroid dehydrogenase (3BHSD) and were present only in cells with high concomitant expression of both proteins, a phenotype unique to Leydig cells and LCTs. Leydig cells from AIS cases lack RCs due to decreased expression of 3BHSD. Calretinin is decreased in testicular adrenal-like tumors and absent in normal adrenocortical cells, which explain why they lack RCs. Calretinin expression in androgen-producing cells is independent from androgen receptors and androgen synthesis. RCs represent for the most part, if not exclusively, crystallized forms of a 3BHSD/calretinin complex. Androgen-producing cells containing and lacking RCs differ mainly in the level of expression of these proteins and androgen receptors.
Introduction
In a recent study, we showed that Reinke crystals (RCs) are invariably present in a subset of Leydig cells from a normal testis, that the crystals dissolve rapidly in formalin fixative and slowly in alcohol, and that they stain specifically with antibodies against 3β-hydroxysteroid dehydrogenase (3BHSD). Contrary to previous assertions, RCs lack expression of nestin and are not products of degradation [1] [2] [3] . We have now studied neoplastic and non-neoplastic examples of androgenproducing cells known to harbor or lack RCs. The goal of this study was to determine if consistent immunophenotypic differences exist between these morphologically and biologically closely related subgroups and if these differences provide further insight on the nature of RCs.
Materials and methods
The pathology databases from five hospitals affiliated with the University of Minnesota Medical School were searched for cases with testicular sex cord-stromal cell tumors (SCSCTs), testicular specimens from cases with androgen insensitivity syndrome (AIS), and cases with adrenogenital syndrome (AGS). Microscopic slides of potential study cases were reviewed. Confirmed cases with available paraffinembedded blocks were included in the study. Participating institutions use 10 % buffered formalin for tissue fixation. Sertoli cell lesions were excluded from the analysis. The lesions were subclassified using the current World Health Organization and Armed Forces Institute of Pathology classifications [4, 5] . The number of RCs per slide was semiquantified as follows: absent, scant (less than 5), moderate (5 to 20), and abundant (>20). Crystals were semiquantified separately in tumoral and non-tumoral entities. Immunohistochemical studies included cytokeratin cocktail (CK) (AE1/AE3+8/18 cocktail, Biocare Medical, catalog # CM162B, Concord CA; dilution 1:900), epithelial membrane antigen (EMA) (Cell Marque, catalog # 247M-95, Rocklin, CA; dilution 1:1000), inhibin A (Novacastra, catalog # NCL-L-Inhibin A, Newcastle upon Tyne, UK; dilution 1:1500), calretinin (Novacastra, catalog # NCL-L-CALRET-566, Newcastle upon Tyne, UK; dilution 1:1200), CD117 (Cell Marque, catalog # 117R-14, Rocklin, CA; dilution 1:300), synaptophysin (Novacastra, catalog # NCL-SYNAP-299, Newcastle upon Tyne, UK; dilution 1:100), CD56 (Biocare Medical, Concord, CA; catalog # CD164A, dilution 1:100), vimentin (Cell Marque, Rocklin, CA; catalog # 347M-14, dilution 1:250), S100 (Novacastra, catalog # CL-L-S100P, Newcastle upon Tyne, UK; dilution 1:1600), testosterone (GeneTex, Irvine, CA; product # GTX72779; dilution, 1:125), androstenedione (ASD) (US Biological, Salem, MA; product # 151581; dilution, 1:100), dehydroepiandrosterone (DHEA) (US Biological; product # 140041; dilution, 1:50), 3BHSD (Santa Cruz Biotechnology, Dallas, TX; product # sc-100466; dilution, 1:250), 17α-hydroxylase/17,20-lyase (CYP17A1) (Santa Cruz Biotechnology; product # sc-46084; Dallas, TX; dilution 1:110), 17β-hydroxysteroid dehydrogenase (17BHSD) (Abcam Inc., Boston, MA; [EP1682Y] ab51045; dilution, 1:50), androgen receptor (Bio SB, Santa Barbara, CA, catalog # BSB 6074), PAX2 (Bio SB, Santa Barbara, CA, catalog # BSB 2566, pre-dilute), and PAX8 (Cell Marque, Rocklin, CA; catalog # 363M-14, predilute). Immunohistochemistry was performed on a Leica BOND-III automated stainer (Leica Biosystems, Melbourne, Australia) using citrate and EDTA buffer antigen retrieval protocols. Dilutions and retrieval methods were optimized in preliminary studies. The full immunohistochemical panel was performed in 17 testes with SCSCTs, 11 of these had lesions included in this study; in the remaining six cases which contained Sertoli cell lesions, only the non-neoplastic cells were evaluated. The panel was also applied to 10 nontumoral adrenal glands from radical nephrectomy cases. A second panel selected because of its discriminative diagnostic power was applied to all 26 study lesions and 10 non-tumoral adrenal glands. The second panel included androgenic hormones, enzymes, and receptors, as well as calretinin, inhibin, and cytokeratin cocktail. For the evaluation of the immunohistochemical stains, a numerical system for grading the intensity of expression was used (1 = weak, 2 = moderate, and 3 = strong), relative to the strongest and negative internal control cells in each preparation. In cases with partial expression of a marker, the percentage of positive cells was recorded. All parameters were evaluated in tumoral and non-tumoral androgen-producing cells present on each study slide. Electronic medical records of identified cases were reviewed for retrieving demographic data, after approval from the respective institutional review boards from the participating institutions.
Results

Clinicopathologic features
The clinicopathologic features are summarized in Table 1 . were discovered incidentally and 26 % (5/19) consulted for pain, one for a testicular mass, and one for gynecomastia. The TART cases were found incidentally. In the TTAGS group, the presenting symptoms were precocious puberty and infertility, and in the AIS group, the presenting symptom was primary amenorrhea. Table 2 summarizes the results of a panel of markers commonly utilized in the work-up of SCSCT performed in a subset of the cases and In adrenocortical cells, CD56 expression is strong in the zona glomerulosa, moderate in the exterior layers of the zona fasciculata, and negative in the internal zona fasciculata and zona reticularis. Pankeratin was diffuse and strong in one of the LCT cases with atypical morphology. In normal Leydig cells, LCTs, LC-AIS, TTAGS, and TARTs, pankeratin expression is nonuniform and highly variable. In the adrenal cortex, pankeratin expression is also non-uniform and highly variable, being more common in the zona glomerulosa, followed by the zonas reticularis and fasciculata. S100 showed partial weak reactivity in normal Leydig cells in a few cases (2/17), but it was negative in the remaining normal Leydig cells, LCTs, LC-AIS, TTAGS, TARTs, and adrenal cortex cells. Synaptophysin showed focal weak staining in a small subset of cells in all the study groups. C-Kit showed weak partial staining in one of the atypical LCT cases, but it was negative in all the remaining groups. EMA, chromogranin, PAX2, and PAX8 were consistently negative in normal Leydig cells, LCTs, LC-AIS, TTAGS, TARTs, and adrenocortical cells. Figure 2 and Table 3 summarize the results of these studies. Normal Leydig cells, LC-AIS, TARTs, and TTAGS show consistent expression of testosterone and DHEA, and variable ASD. Most LCTs have no or decreased expression of the three hormones. In the adrenal cortex, only the zona reticularis is positive for testosterone and DHEA but negative for ASD. Normal Leydig cells, LCTs, and all layers of the adrenal cortex show strong and consistent expression of 3BHSD; by contrast, expression is weak in TARTs, TTAGS, and LC-AIS. Expression of CYP17A1 is strong and consistent in all groups except for the zona glomerulosa of the adrenal cortex. Expression of 17BHSD is variable in normal Leydig cells, LCTs, and TARTs and negative in LC-AIS, TTAGS, and adrenocortical cells. Androgen receptors (ARs) are consistently positive in normal Leydig cells and LCTs; expression in TARTs was weak and focal (∼10 %). In TTAGS, the younger patient (age 6) had a complete loss of AR expression, while the older patient (age 30) retained weak expression in ∼60 % of the cells. In the adrenal cortex, a small subset of cells in the zona glomerulosa (∼20 %) and in the zona fasciculata (∼5 %) show weak AR expression, but the androgen-producing zona reticularis was negative.
Immunohistochemical studies
Endocrine profile
Reinke crystals
RCs were identified in 18/20 (90 %) LCT cases; RCs were not observed in the two cases with atypical morphology. RCs were abundant in 10, moderate in four, and scant in four cases. Non-tumoral Leydig cells were present in adjacent testicular tissue in 16/20 of the specimens with LCTs, and RCs were identified in all cases (100 %): 12 abundant, 3 moderate, and 1 scant. RCs were present in the non-tumoral Leydig cells of the two cases of TART. The two cases of TTAGS did not have normal Leydig cells for evaluation. Crystals were absent in the two cases of AIS. RCs were consistently positive for calretinin and 3BHSD and negative for all the remaining markers. The staining pattern with both antibodies was grumous and discontinuous. Because on immunostained slides the crystals were frequently obscured by cytoplasmic staining, we performed several dilutions and combinations of calretinin and 3BHSD antibodies to improve the crystal to cytoplasmic contrast with success (Fig. 3) ; however, the crystals continued to appear as grumous sausage-shaped formations instead of the crisp elegant structures observed on hematoxylin and eosin.
Discussion
RCs, originally described in 1896, are unique to Leydig cells and LCTs and help separate them from their close relatives TARTs, TTAGS, and adrenal cortex cells. We recently clarified several misconceptions about RCs: we demonstrated that RCs are almost invariably present in a subset of Leydig cells in normal testes as originally described by Friedrich Reinke, but their number is variable; we showed that RCs are amphiphilic: they dissolve rapidly in formalin and slowly in alcohol; we demonstrated that RCs stain specifically with antibodies against 3BHSD and disproved the previous assertion that the crystals are positive for nestin, and finally, we demonstrated that they do not represent waste/degenerative products as previously reported [2, 3] . Embryologically, the SCSCs of the gonads and the adrenal cortex share a common origin from the cells of the adrenogenital primordium [6] . This explains the close immunomorphologic resemblance between all these cell groups [7] . While Sertoli cells develop highly specialized functions directed at providing an optimal environment for regulation of spermatogenesis [6] [7] [8] , Leydig cells, testicular adrenal-like cells, and adrenocortical cells remain to be primary endocrine/paracrine cells [9] . In the current study, we found RCs in all cases containing normal Leydig cells and in 90 % of LCT cases, a percentage that is much higher than the one third of cases described in reference books [4, 5] . This discrepancy may be explained by fixation times and the time and effort dedicated to this task. By immunohistochemistry, in addition to 3BHSD, RCs are also positive for calretinin. Among steroid-producing cells, the main difference between cells containing and lacking RCs was the level of coexpression of 3BHSD and calretinin. Strong coexpression of both proteins was unique to normal Leydig cells and LCTs. Figure 1 shows the different expression levels of 3BHSD and calretinin in all the study groups. Our results indicate that RCs represent for the most part, if not exclusively, crystallized forms of a 3BHSD/calretinin complex. RCs did not contain androgens; however, given the hydrosoluble properties of the crystals, it is possible that the presence of lipophilic hormones in the cytoplasm may be necessary or contributes to the crystallization process. Leydig cells from AIS cases express high calretinin but low 3BHSD, TTAGS and TARTs show decreased expression of both 3BHSD and calretinin, and adrenocortical cells show high 3BHSD but absent calretinin, while the expression of androgens is maintained in all these groups. All these groups lack RCs, suggesting that a high concentration of both proteins is necessary for the crystallization process. The rare cases of adrenal neoplasms containing RCs [10] can probably be explained by the frequent aberrant expression of calretinin by adrenal neoplasms [11] , which is not present in normal adrenocortical cells. If concurrent high coexpression level of 3BHSD/calretinin occurs in any given steroid-producing tumor, crystallization may happen. Crystalline structures resembling RCs were observed by Magalhães in periendothelial spindle cells in the adrenal gland of two thirds of patients who underwent adrenalectomy for Buerger's disease [12] . The crystals were absent on the histologic preparations and were only identified by electron microscopy. These spindle cells lacked the ultrastructural features of adrenocortical cells and resembled fibroblasts. In our study, we did not identify any population of spindle cells coexpressing 3BHSD/ calretinin in the 10 studied normal adrenal glands. Despite their intra-abdominal location, Leydig cells from AIS cases lack RCs, and this dispels the notion that formation of RCs is caused by an increased core body temperature [3] . The lack of ARs in LC-AIS correlated with markedly reduced expression of 3BHSD but did not affect calretinin. This indicates that under physiologic conditions, ARs either upregulate or prevent the downregulation of 3BHSD but do not affect calretinin. Calretinin is not present in androgen-producing adrenal cortex cells, indicating that it does not participate in androgen synthesis and that it is independent from adrenocorticotropic hormone receptor (ACTH-R). The origin of testicular adrenal rest tumors, TARTs, and TTAGS is not clear; it has been hypothesized that they represent ectopic adrenal tissue or that they arise from pluripotent perivascular cells; however, experimental support is lacking [13] [14] [15] [16] . Our work shows that TARTs and TTAGS show a unique phenotype between Leydig cells and androgen-producing adrenocortical cells. All these groups show similar expression of inhibin and androgens; however, TARTs/TTAGS show reduced expression of 3BHSD compared to Leydig and adrenocortical cells, and the expression of calretinin and androgen receptors is intermediate between Leydig and adrenocortical cells, in which these proteins are either strongly expressed or negative, respectively. In contrast to what has been previously reported, synaptophysin and CD56 immunostains lacked a discriminative power for separating testicular adrenal-like lesions from LCTs; expression of CD56 is consistent in both lesions, while expression of synaptophysin is erratic [13] [14] [15] . We tried to determine if differences in the expression of ACTH-Rs exist between LCs, testicular adrenal-like lesions, and adrenocortical cells as suggested by the pathophysiology of adrenogenital syndrome; however, after testing several commercially available antibodies, we did not find one with adequate specificity for performing these studies. Finally, LCTs compared to 
Conclusions
We found RCs in 90 % of LCT cases, a percentage that is much higher than what has been described in reference books. We also demonstrated consistent immuno phenotypic differences between the different groups of normal and neoplastic androgen-producing cells and between androgen-producing cells containing and lacking RCs. The main differences among these groups were in the level of expression of 3BHSD, calretinin, and AR. We found that RCs stain specifically for 3BHSD and calretinin, indicating that they represent crystallized forms of a 3BHSD/calretinin complex. The main difference between androgen-producing cells containing or lacking RCs is the level of expression of these two proteins; crystals are only present in cells with strong concomitant expression of both proteins, a feature unique to Leydig cells and LCTs. Our findings clarify previously unknown aspects of normal and neoplastic androgen-producing cell groups with overlapping morphologic and biological features and the composition of Reinke crystals. It would have been important to determine if differences in expression of ACTH-Rs exist between these cell groups; unfortunately, we were not able to find a reliable antibody for performing these studies.
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